Report Detail

Pharma & Healthcare Global Gastroesophageal Reflux Disease Therapeutics Market Insights, Forecast to 2025

  • RnM2312773
  • |
  • 07 August, 2018
  • |
  • Global
  • |
  • 94 Pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

Table of Contents

    1 Study Coverage

    • 1.1 Gastroesophageal Reflux Disease Therapeutics Product
    • 1.2 Key Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Gastroesophageal Reflux Disease Therapeutics Market Size Growth Rate by Type
      • 1.4.2 Antacids
      • 1.4.3 H2 Receptor Blockers
      • 1.4.4 Proton Pump Inhibitors (PPIs)
      • 1.4.5 Pro-kinetic Agents
      • 1.4.6 Others
    • 1.5 Market by Application
      • 1.5.1 Global Gastroesophageal Reflux Disease Therapeutics Market Size Growth Rate by Application
      • 1.5.2 Hospital Pharmacy
      • 1.5.3 Drug Stores
      • 1.5.4 General Stores
      • 1.5.5 Supermarkets
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Gastroesophageal Reflux Disease Therapeutics Market Size
      • 2.1.1 Global Gastroesophageal Reflux Disease Therapeutics Revenue 2016-2025
      • 2.1.2 Global Gastroesophageal Reflux Disease Therapeutics Sales 2016-2025
    • 2.2 Gastroesophageal Reflux Disease Therapeutics Growth Rate by Regions
      • 2.2.1 Global Gastroesophageal Reflux Disease Therapeutics Sales by Regions
      • 2.2.2 Global Gastroesophageal Reflux Disease Therapeutics Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Gastroesophageal Reflux Disease Therapeutics Sales by Manufacturers
      • 3.1.1 Gastroesophageal Reflux Disease Therapeutics Sales by Manufacturers
      • 3.1.2 Gastroesophageal Reflux Disease Therapeutics Sales Market Share by Manufacturers
      • 3.1.3 Global Gastroesophageal Reflux Disease Therapeutics Market Concentration Ratio (CR5 and HHI)
    • 3.2 Gastroesophageal Reflux Disease Therapeutics Revenue by Manufacturers
      • 3.2.1 Gastroesophageal Reflux Disease Therapeutics Revenue by Manufacturers (2016-2018)
      • 3.2.2 Gastroesophageal Reflux Disease Therapeutics Revenue Share by Manufacturers (2016-2018)
    • 3.3 Gastroesophageal Reflux Disease Therapeutics Price by Manufacturers
    • 3.4 Gastroesophageal Reflux Disease Therapeutics Manufacturing Base Distribution, Product Types
      • 3.4.1 Gastroesophageal Reflux Disease Therapeutics Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Gastroesophageal Reflux Disease Therapeutics Product Category
      • 3.4.3 Date of International Manufacturers Enter into Gastroesophageal Reflux Disease Therapeutics Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type

    • 4.1 Global Gastroesophageal Reflux Disease Therapeutics Sales by Type
    • 4.2 Global Gastroesophageal Reflux Disease Therapeutics Revenue by Type
    • 4.3 Gastroesophageal Reflux Disease Therapeutics Price by Type

    5 Breakdown Data by Application

    • 5.1 Overview
    • 5.2 Global Gastroesophageal Reflux Disease Therapeutics Breakdown Data by Application

    6 North America

    • 6.1 North America Gastroesophageal Reflux Disease Therapeutics by Countries
      • 6.1.1 North America Gastroesophageal Reflux Disease Therapeutics Sales by Countries
      • 6.1.2 North America Gastroesophageal Reflux Disease Therapeutics Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Gastroesophageal Reflux Disease Therapeutics by Type
    • 6.3 North America Gastroesophageal Reflux Disease Therapeutics by Application
    • 6.4 North America Gastroesophageal Reflux Disease Therapeutics by Company

    7 Europe

    • 7.1 Europe Gastroesophageal Reflux Disease Therapeutics by Countries
      • 7.1.1 Europe Gastroesophageal Reflux Disease Therapeutics Sales by Countries
      • 7.1.2 Europe Gastroesophageal Reflux Disease Therapeutics Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Gastroesophageal Reflux Disease Therapeutics by Type
    • 7.3 Europe Gastroesophageal Reflux Disease Therapeutics by Application
    • 7.4 Europe Gastroesophageal Reflux Disease Therapeutics by Company

    8 Asia Pacific

    • 8.1 Asia Pacific Gastroesophageal Reflux Disease Therapeutics by Countries
      • 8.1.1 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Sales by Countries
      • 8.1.2 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Gastroesophageal Reflux Disease Therapeutics by Type
    • 8.3 Asia Pacific Gastroesophageal Reflux Disease Therapeutics by Application
    • 8.4 Asia Pacific Gastroesophageal Reflux Disease Therapeutics by Company

    9 Central & South America

    • 9.1 Central & South America Gastroesophageal Reflux Disease Therapeutics by Countries
      • 9.1.1 Central & South America Gastroesophageal Reflux Disease Therapeutics Sales by Countries
      • 9.1.2 Central & South America Gastroesophageal Reflux Disease Therapeutics Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Gastroesophageal Reflux Disease Therapeutics by Type
    • 9.3 Central & South America Gastroesophageal Reflux Disease Therapeutics by Application
    • 9.4 Central & South America Gastroesophageal Reflux Disease Therapeutics by Company

    10 Middle East and Africa

    • 10.1 Middle East and Africa Gastroesophageal Reflux Disease Therapeutics by Countries
      • 10.1.1 Middle East and Africa Gastroesophageal Reflux Disease Therapeutics Sales by Countries
      • 10.1.2 Middle East and Africa Gastroesophageal Reflux Disease Therapeutics Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Gastroesophageal Reflux Disease Therapeutics by Type
    • 10.3 Middle East and Africa Gastroesophageal Reflux Disease Therapeutics by Application
    • 10.4 Middle East and Africa Gastroesophageal Reflux Disease Therapeutics by Company

    11 Company Profiles

    • 11.1 AstraZeneca
      • 11.1.1 AstraZeneca Company Details
      • 11.1.2 Company Description
      • 11.1.3 Sales, Revenue and Gross Margin of Gastroesophageal Reflux Disease Therapeutics
      • 11.1.4 Gastroesophageal Reflux Disease Therapeutics Product Description
      • 11.1.5 Recent Development
    • 11.2 Eisai
      • 11.2.1 Eisai Company Details
      • 11.2.2 Company Description
      • 11.2.3 Sales, Revenue and Gross Margin of Gastroesophageal Reflux Disease Therapeutics
      • 11.2.4 Gastroesophageal Reflux Disease Therapeutics Product Description
      • 11.2.5 Recent Development
    • 11.3 Takeda Pharmaceutical
      • 11.3.1 Takeda Pharmaceutical Company Details
      • 11.3.2 Company Description
      • 11.3.3 Sales, Revenue and Gross Margin of Gastroesophageal Reflux Disease Therapeutics
      • 11.3.4 Gastroesophageal Reflux Disease Therapeutics Product Description
      • 11.3.5 Recent Development
    • 11.4 GlaxoSmithKline
      • 11.4.1 GlaxoSmithKline Company Details
      • 11.4.2 Company Description
      • 11.4.3 Sales, Revenue and Gross Margin of Gastroesophageal Reflux Disease Therapeutics
      • 11.4.4 Gastroesophageal Reflux Disease Therapeutics Product Description
      • 11.4.5 Recent Development
    • 11.5 Johnson & Johnson
      • 11.5.1 Johnson & Johnson Company Details
      • 11.5.2 Company Description
      • 11.5.3 Sales, Revenue and Gross Margin of Gastroesophageal Reflux Disease Therapeutics
      • 11.5.4 Gastroesophageal Reflux Disease Therapeutics Product Description
      • 11.5.5 Recent Development
    • 11.6 Daewoong Pharmaceutical
      • 11.6.1 Daewoong Pharmaceutical Company Details
      • 11.6.2 Company Description
      • 11.6.3 Sales, Revenue and Gross Margin of Gastroesophageal Reflux Disease Therapeutics
      • 11.6.4 Gastroesophageal Reflux Disease Therapeutics Product Description
      • 11.6.5 Recent Development
    • 11.7 Ironwood Pharmaceuticals
      • 11.7.1 Ironwood Pharmaceuticals Company Details
      • 11.7.2 Company Description
      • 11.7.3 Sales, Revenue and Gross Margin of Gastroesophageal Reflux Disease Therapeutics
      • 11.7.4 Gastroesophageal Reflux Disease Therapeutics Product Description
      • 11.7.5 Recent Development
    • 11.8 Rottapharm Madaus
      • 11.8.1 Rottapharm Madaus Company Details
      • 11.8.2 Company Description
      • 11.8.3 Sales, Revenue and Gross Margin of Gastroesophageal Reflux Disease Therapeutics
      • 11.8.4 Gastroesophageal Reflux Disease Therapeutics Product Description
      • 11.8.5 Recent Development
    • 11.9 Peer Medical
      • 11.9.1 Peer Medical Company Details
      • 11.9.2 Company Description
      • 11.9.3 Sales, Revenue and Gross Margin of Gastroesophageal Reflux Disease Therapeutics
      • 11.9.4 Gastroesophageal Reflux Disease Therapeutics Product Description
      • 11.9.5 Recent Development
    • 11.10 Reviva Pharmaceuticals
      • 11.10.1 Reviva Pharmaceuticals Company Details
      • 11.10.2 Company Description
      • 11.10.3 Sales, Revenue and Gross Margin of Gastroesophageal Reflux Disease Therapeutics
      • 11.10.4 Gastroesophageal Reflux Disease Therapeutics Product Description
      • 11.10.5 Recent Development

    12 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 12.1 Market Opportunities and Drivers
    • 12.2 Market Challenges
    • 12.3 Market Risks/Restraints
    • 12.4 Key World Economic Indicators

    13 Value Chain and Sales Channels Analysis

    • 13.1 Value Chain Analysis
      • 13.1.1 Typical Suppliers of Key Gastroesophageal Reflux Disease Therapeutics Raw Material
      • 13.1.2 Gastroesophageal Reflux Disease Therapeutics Customers
    • 13.2 Sales Channels Analysis
      • 13.2.1 Sales Channels Analysis
      • 13.2.2 Distributors

    14 Research Findings and Conclusion

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 15.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Author Details

      This report studies the global market size of Gastroesophageal Reflux Disease Therapeutics in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Gastroesophageal Reflux Disease Therapeutics in these regions.
      This research report categorizes the global Gastroesophageal Reflux Disease Therapeutics market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porter's Five Forces Analysis.

      In 2017, the global Gastroesophageal Reflux Disease Therapeutics market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. The objectives of this study are to define, segment, and project the size of the Gastroesophageal Reflux Disease Therapeutics market based on company, product type, application and key regions.

      The various contributors involved in the value chain of Gastroesophageal Reflux Disease Therapeutics include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in the Gastroesophageal Reflux Disease Therapeutics include
      AstraZeneca
      Eisai
      Takeda Pharmaceutical
      GlaxoSmithKline
      Johnson & Johnson
      Daewoong Pharmaceutical
      Ironwood Pharmaceuticals
      Rottapharm Madaus
      Peer Medical
      Reviva Pharmaceuticals

      Market Size Split by Type
      Antacids
      H2 Receptor Blockers
      Proton Pump Inhibitors (PPIs)
      Pro-kinetic Agents
      Others
      Market Size Split by Application
      Hospital Pharmacy
      Drug Stores
      General Stores
      Supermarkets

      Market size split by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Gastroesophageal Reflux Disease Therapeutics market size (value & volume) by company, key regions/countries, products and application, history data from 2013 to 2017, and forecast to 2025.
      To understand the structure of Gastroesophageal Reflux Disease Therapeutics market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Gastroesophageal Reflux Disease Therapeutics manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
      To analyze the Gastroesophageal Reflux Disease Therapeutics with respect to individual growth trends, future prospects, and their contribution to the total market.
      To project the value and volume of Gastroesophageal Reflux Disease Therapeutics submarkets, with respect to key regions (along with their respective key countries).
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
      To strategically profile the key players and comprehensively analyze their growth strategies.

      In this study, the years considered to estimate the market size of Gastroesophageal Reflux Disease Therapeutics are as follows:
      History Year: 2013-2017
      Base Year: 2017
      Estimated Year: 2018
      Forecast Year 2018 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Gastroesophageal Reflux Disease Therapeutics market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.


      Summary:
      Get latest Market Research Reports on Gastroesophageal Reflux Disease Therapeutics . Industry analysis & Market Report on Gastroesophageal Reflux Disease Therapeutics is a syndicated market report, published as Global Gastroesophageal Reflux Disease Therapeutics Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Gastroesophageal Reflux Disease Therapeutics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,900.00
      $7,800.00
      3,026.36
      6,052.71
      3,501.44
      7,002.89
      423,309.90
      846,619.80
      277,407.78
      554,815.56
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report